1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aarey Drugs & Pharmaceuticals Limited

Aarey Drugs & Pharmaceuticals Limited

AAREYDRUGS.NS
Aarey Drugs & Pharmaceuticals LimitedIN flagNational Stock Exchange of India
84.52
INR
-1.72
- -
2.40BMarket Cap

Total Valuation

Aarey Drugs & Pharmaceuticals Limited carries a market capitalization of 2.40B, placing it among publicly traded companies globally. Its enterprise value stands at 1.91B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.40B
Enterprise Value1.91B

Share Statistics

Aarey Drugs & Pharmaceuticals Limited currently has 28.35M shares outstanding.

Shares Outstanding28.35M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Aarey Drugs & Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 31.89. The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 5.07.

PE Ratio31.89
PS Ratio0.31
PB Ratio5.07
P/TBV Ratio0.96
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Aarey Drugs & Pharmaceuticals Limited trades at an EV/EBITDA multiple of 44.14 and an EV/FCF ratio of 45.66. The EV/Sales ratio of 0.40 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 44.14 provides insight into valuation relative to core operating earnings.

EV / Sales0.40
EV / EBITDA44.14
EV / EBIT44.14
EV / FCF45.66

Financial Position

Aarey Drugs & Pharmaceuticals Limited maintains a current ratio of 1.81, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.21, indicating elevated leverage, while an interest coverage ratio of 0.86 demonstrates limited ability to service its debt obligations.

Current Ratio1.81
Quick Ratio0.02
Debt / Equity33.21
Debt / EBITDA11.56
Interest Coverage0.86

Financial Efficiency

Aarey Drugs & Pharmaceuticals Limited posts a return on equity of 7.93 and a return on invested capital of 1.93.

Return on Equity (ROE)7.93
Return on Assets (ROA)1.54
Return on Invested Capital (ROIC)1.93
Return on Capital Employed (ROCE)8.75
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover10.45

Taxes

Over the trailing twelve months, Aarey Drugs & Pharmaceuticals Limited has paid 8.92M in income taxes, reflecting an effective tax rate of 16.48.

Income Tax8.92M
Effective Tax Rate16.48

Stock Price Statistics

Aarey Drugs & Pharmaceuticals Limited's stock has gained approximately 19.14294% over the past 52 weeks. The 50-day moving average sits at 84.89, while the 200-day moving average is 77.68.

Beta (5Y)N/A
52-Week Price Change19.14294%
50-Day Moving Average84.89
200-Day Moving Average77.68
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Aarey Drugs & Pharmaceuticals Limited generated 4.72B in revenue and converted that into 45.22M in net income, yielding earnings per share of 1.59. EBITDA reached 43.22M, while operating income came in at 43.22M.

Revenue4.72B
Gross Profit177.62M
Operating Income43.22M
Pretax Income54.14M
Net Income45.22M
EBITDA43.22M
EBIT43.22M
Earnings Per Share (EPS)1.59

Balance Sheet

Aarey Drugs & Pharmaceuticals Limited holds 33.98M in cash and equivalents against 499.62M in total debt, resulting in a net debt position of 485.63M. Total book value stands at 284.54M, with working capital of 1.18B providing operational flexibility.

Cash & Cash Equivalents33.98M
Total Debt499.62M
Net Debt485.63M
Equity (Book Value)284.54M
Book Value Per Share10.01
Working Capital1.18B

Margins

Aarey Drugs & Pharmaceuticals Limited operates with a gross margin of 3.76, reflecting its pricing power and cost economics. The operating margin of 0.92 and net profit margin of 0.96 provide insight into operational efficiency.

Gross Margin3.76
Operating Margin0.92
Pretax Margin1.15
Profit Margin0.96
EBITDA Margin0.92

Scores

Aarey Drugs & Pharmaceuticals Limited posts an Altman Z-Score of 2.70, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.70